SCHEMBL908349

SCHEMBL908349

Fc1ccc2c(c1)CC1OC1O2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.38
HTR2A P28223 2/20 0.38
MLNR O43193 1/20 0.38
ADRB2 P07550 1/20 0.38
ADRB1 P08588 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
CHRM1 P11229 1/20 0.38
KCNE1 P15382 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
CNR1 P21554 1/20 0.38
SLC6A2 P23975 1/20 0.38
NPY1R P25929 1/20 0.38
HTR2C P28335 1/20 0.38
AVPR2 P30518 1/20 0.38
SLC6A4 P31645 1/20 0.38
ADRA1A P35348 1/20 0.38
OPRM1 P35372 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8887689 0.78 DRD2 (0.40) DRD2HTR2AMLNRADRB2ADRB1
SCHEMBL9358376 0.75 PNMT (0.36) DRD2DRD3DPP4
SCHEMBL15724653 0.74 TDP1 (0.56) DRD2HTR2AMLNRADRB2ADRB1
SCHEMBL15749929 0.74 TDP1 (0.56) DRD2HTR2AMLNRADRB2ADRB1
SCHEMBL36938 0.73 CHRM2 (0.46) ADORA3CHRM1HRH3MAOB
SCHEMBL25424228 0.72 CHRM2 (0.45) CHRM1HRH3MAOB
SCHEMBL1286412 0.72 CHRM2 (0.45) ADORA3CHRM1HRH3MAOB
SCHEMBL162329 0.72 CHRM2 (0.45) ADORA3CHRM1HRH3MAOB
SCHEMBL22583920 0.72 CHRM2 (0.45) ADORA3CHRM1HRH3MAOB
SCHEMBL10699051 0.72 CHRM2 (0.45) ADORA3CHRM1HRH3MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10392361-B2 Process for the synthesis of intermediates of Nebivolol MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) 2019-08-27 US disclosed
EP-2265596-B1 PROCESS FOR PREPARING NEBIVOLOL ZACH SYSTEM SPA (IT) 2016-06-01 EP disclosed
US-8981127-B2 Method for preparing nebivolol ZACH SYSTEM (FR) 2015-03-17 US disclosed
US-8969597-B2 Process for preparing nebivolol ZACH SYSTEM S.P.A. (IT) 2015-03-03 US disclosed
EP-2456768-B1 PROCESS FOR PREPARING NEBIVOLOL ZACH SYSTEM SPA (IT) 2014-11-19 EP disclosed
EP-2078005-B1 PROCESS FOR PREPARING NEBIVOLOL ZACH SYSTEM SPA (IT) 2013-05-08 EP disclosed
CN-101952270-B Process for preparing nebivolol ZACH SYSTEM SPA 2013-04-24 CN disclosed
EP-2102196-B1 PROCESS FOR PREPARING NEBIVOLOL ZACH SYSTEM SPA (IT) 2012-08-01 EP disclosed
EP-2456768-A1 PROCESS FOR PREPARING NEBIVOLOL ZaCh System S.p.A. (IT) 2012-05-30 EP disclosed
CN-102471325-A Process for preparing nebivolol ZACH SYSTEM SPA 2012-05-23 CN disclosed
EP-2265596-A2 PROCESS FOR PREPARING NEBIVOLOL ZaCh System S.p.A. (IT) 2010-12-29 EP disclosed
US-20100076206-A1 PROCESS FOR PREPARING NEBIVOLOL ZACH SYSTEM S.P.A. (IT) 2010-03-25 US disclosed
US-20100069652-A1 The Process for Preparing Nebivolol ZACH SYSTEM S.P.A. (IT) 2010-03-18 US disclosed
WO-2009121710-A2 PROCESS FOR PREPARING NEBIVOLOL ZACH SYSTEM S.P.A. (IT) 2009-10-08 WO disclosed
EP-2102196-A1 PROCESS FOR PREPARING NEBIVOLOL ZaCh System S.p.A. (IT) 2009-09-23 EP disclosed
CN-101541791-A Process for preparing nebivolol ZACH SYSTEM SPA (IT) 2009-09-23 CN disclosed
CN-101522656-A Process for preparing nebivolol ZACH SYSTEM SPA (IT) 2009-09-02 CN disclosed
EP-2078005-A2 PROCESS FOR PREPARING NEBIVOLOL ZaCh System S.p.A. (IT) 2009-07-15 EP disclosed
WO-2008064826-A1 PROCESS FOR PREPARING NEBIVOLOL ZACH SYSTEM S.P.A. (IT) 2008-06-05 WO disclosed
WO-2008040528-A2 PROCESS FOR PREPARING NEBIVOLOL ZACH SYSTEM S.P.A. (IT) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076206-A1 PROCESS FOR PREPARING NEBIVOLOL ADRB1, ADRB2, ADRA1B DRD2 124/4885HTR2A 1102/4885MLNR 812/4885
US-10392361-B2 Process for the synthesis of intermediates of Nebivolol ADRB3, ADRB2, ADRB1 DRD2 388/4885HTR2A 658/4885MLNR 2010/4885
US-20100069652-A1 The Process for Preparing Nebivolol CYP4A11, ADRB1, CYP4B1 DRD2 377/4885HTR2A 743/4885MLNR 504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.